Califf cau­tions against low­er­ing FDA stan­dards; Ed­i­tas out­lines $1B mile­stone pack­age

→ Ex-FDA Com­mis­sion­er Robert Califf is back at Duke. And he has some ad­vice for the Trump ad­min­is­tra­tion as it fol­lows through on plans to re­or­ga­nize the agency and cut re­view times. “Short­en­ing and ex­pe­dit­ing is a great idea, but it needs to be done with­out low­er­ing the stan­dards,” Califf told Duke’s The Chron­i­cle. In the stu­dent news­pa­per, Califf point­ed out that more than 90 per­cent of drugs en­ter­ing clin­i­cal tri­als cur­rent­ly do not make it to the mar­ket. If reg­u­la­tions are loos­ened to ap­prove those, he said “a lot of peo­ple are go­ing to get hurt or end up tak­ing in­ef­fec­tive drugs.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA